Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $21.38

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $21.38.

YMAB has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, November 15th.

Y-mAbs Therapeutics Stock Up 3.1 %

Shares of YMAB opened at $10.41 on Thursday. Y-mAbs Therapeutics has a 52 week low of $5.29 and a 52 week high of $20.90. The stock has a market cap of $466.26 million, a P/E ratio of -19.28 and a beta of 0.68. The business’s 50 day moving average price is $13.69 and its 200-day moving average price is $12.88.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the firm earned ($0.18) EPS. On average, equities analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. This represents a 14.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the sale, the insider now owns 97,681 shares in the company, valued at approximately $1,315,763.07. This trade represents a 39.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock valued at $1,338,100 in the last 90 days. Insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics during the 3rd quarter valued at $44,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares during the period. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics during the 3rd quarter worth about $133,000. Finally, SG Americas Securities LLC bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at about $178,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.